USE OF 8-SUBSTITUTED-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
    12.
    发明申请
    USE OF 8-SUBSTITUTED-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES 失效
    使用8-取代-6,7,8,9-四氢嘧啶并[1,2-a]嘧啶-4-酮衍生物

    公开(公告)号:US20080021046A1

    公开(公告)日:2008-01-24

    申请号:US11764374

    申请日:2007-06-18

    CPC分类号: A61K31/519 C07D487/04

    摘要: The invention relates to use of substituted-pyrimidone derivatives represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, R4, R5, n, p and q are as defined herein. More specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of GSK3β, such as Pick's disease among various other diseases as claimed herein.

    摘要翻译: 本发明涉及由式(I)表示的取代嘧啶酮衍生物或其盐的用途:其中X,Y,R 1,R 2,R 3,R 4,R 5,n,p和q如本文所定义。 更具体地,本发明涉及包含所述衍生物或其盐作为活性成分的药物,其用于预防和/或治疗由GSK3β的异常活性引起的疾病,例如各种其他疾病中的皮克病,例如 在此。

    HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
    20.
    发明申请
    HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES 失效
    异噻唑基取代的2-吡啶基和2-吡啶基-6,7,8,9-四氢吡啶并[1,2-a]嘧啶-4-酮衍生物

    公开(公告)号:US20070225300A1

    公开(公告)日:2007-09-27

    申请号:US11749349

    申请日:2007-05-16

    IPC分类号: A61K31/519

    摘要: The invention relates to use of a pyrimidone derivative represented by formula (I) or a salt thereof wherein: X, Y, R1, R2, R3, R4, R5, m, n and p are as defined herein. In particular, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease.

    摘要翻译: 本发明涉及由式(I)表示的嘧啶酮衍生物或其盐,其中:X,Y,R 1,R 2,R 3,R 4,R 5,m,n和p如本文所定义。 特别地,本发明涉及包含所述衍生物或其盐作为活性成分的药物,其用于预防和/或治疗由GSK3β或GSK3β和cdk5 / p25的异常活性引起的神经变性疾病的预防和/或治疗,例如 阿尔茨海默病。